demerger, page-5

l would have thought some significant news from the oncology side would be a precursor to the spin off so some reasonable value is created. Otherwise existing shareholders will face unnecessary extra dilution due to a low SP at float and the need to raise more cash. Dont forget that a partnering deal is probably 2 years+ away and its only then that more capital will arrive.

They've done it to us before and it could happen again.

This market is a bad time to consider the split and PS recognised market conditions as a timing factor in his comments from late last year. Well the Australian market is suffering from excessive paranoia and is one of the worst performers in the developed world as things stand.

And of course the usual cone of silence prevails.